- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04664933
Intra-arterial Neuroprotective Strategy for Ischemic STroke Patients With Endovascular Therapy (INSIST-ET)
May 23, 2023 updated by: Hui-Sheng Chen
Intra-arterial Neuroprotective Strategy for Ischemic STroke Patients With Endovascular Therapy (INSIST-ET): One Single Center, Safety and Feasibility Study
To explore the safety and feasibility of intra-arterial neuroprotective strategy in acute ischemic stroke patients who received recanalization operation.
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Shenyang, China, 110016
- Recruiting
- Department of Neurology, General Hospital of Northern Theater Command
-
Contact:
- Hui-Sheng Chen, Ph.D.
- Phone Number: +86 13352452086
- Email: chszh@aliyun.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age ≥18 years;
- Acute ischemic stroke patients who is eligible for endovascular treatment;
- Signed informed consent.
Exclusion Criteria:
- Modified Rankin Score >2 caused by a history of prior stroke;
- Coagulation disorders, systematic hemorrhagic tendency, thrombocytopenia (<80000/mm3);
- Severe hepatic or renal dysfunction, increase in ALT or AST (more than 2 times of upper limit of normal value), increase in serum creatinine (more than 1.5 times of upper limit of normal value) or requiring dialysis;
- Severe hypertension (systolic blood pressure over 200mmHg or diastolic blood pressure over 110 mmHg);
- Unsuitable for this clinical studies assessed by researcher.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intra-arterial administration of 3-n-butylphthalide
Intra-arterial administration of 3-n-butylphthalide for 16 to 24 hours during and after the operation at 17.36 to 26.04 ug/min.
|
Intra-arterial administration of 3-n-butylphthalide for 16 to 24 hours during and after the operation at 17.36 to 26.04 ug/min
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of server adverse events
Time Frame: 48 hours
|
server adverse events including femoral artery dissection, local thrombosis, seudoaneurysm, arteriovenousfistula, etc.
|
48 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of symptomatic intracranial hemorrhage (sICH)
Time Frame: 48 hours
|
sICH was defined as 4 or more increase in NIHSS caused by hemorrhage
|
48 hours
|
Proportion of patients with modified Rankin Score 0 to 1
Time Frame: 90 days
|
Proportion of patients with modified Rankin Score 0 to 1
|
90 days
|
Proportion of patients with modified Rankin Score 0 to 2
Time Frame: 90 days
|
Proportion of patients with modified Rankin Score 0 to 2
|
90 days
|
Modified Rankin Score
Time Frame: 90 days
|
Modified Rankin Score
|
90 days
|
Decrease in national institutes of health stroke scale (NIHSS)
Time Frame: 48 hours
|
Decrease in NIHSS scoring at 48 hours after the treatment
|
48 hours
|
Proportion of intraparenchymal hemorrhage (PH1 and PH2)
Time Frame: 48 hours
|
Proportion of intraparenchymal hemorrhage (PH1 and PH2) within 48 hours after the treatment
|
48 hours
|
Changes in cerebral edema
Time Frame: 48 hours
|
Cerebral edema was determined by cerebral volume or midline shift
|
48 hours
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Differences in serum factors levels and blood gas in diverse vessel region
Time Frame: Hour 0
|
Differences in serum factors levels and blood gas in diverse vessel region
|
Hour 0
|
Changes in serum factors levels
Time Frame: 30 minutes, 24 hours
|
changes in serum factors levels before and at different timepoints after recanalization
|
30 minutes, 24 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 1, 2020
Primary Completion (Estimated)
December 31, 2023
Study Completion (Estimated)
December 31, 2023
Study Registration Dates
First Submitted
November 30, 2020
First Submitted That Met QC Criteria
December 6, 2020
First Posted (Actual)
December 11, 2020
Study Record Updates
Last Update Posted (Actual)
May 25, 2023
Last Update Submitted That Met QC Criteria
May 23, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- K (2020) 32
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke, Ischemic
-
Nordsjaellands HospitalRigshospitalet, Denmark; Metropolitan University CollegeCompletedTransient Ischemic Attack | Stroke, Ischemic | Stroke HemorrhagicDenmark
-
University of CalgaryThe George Institute for Global Health, AustraliaNot yet recruitingAcute Ischemic Stroke AIS | Stroke, Acute, Stroke Ischemic | Stroke AcuteCanada, Australia
-
Second Affiliated Hospital, School of Medicine,...Shanghai Zhongshan Hospital; First Affiliated Hospital of Wenzhou Medical University and other collaboratorsRecruitingAcute Ischemic Stroke and Transient Ischemic AttacksChina
-
Medtronic Cardiac Rhythm and Heart FailureMedtronic Bakken Research CenterCompletedCryptogenic Symptomatic Transient Ischemic Attack | Cryptogenic Ischemic StrokeNetherlands, United States, France, Belgium, Germany, Sweden, Italy, Austria, Canada, Denmark, Finland, Greece, Slovakia, Spain
-
University Hospital, BrestCompletedStroke, Ischemic | Stroke HemorrhagicFrance
-
Umbria Bioengineering TechnologiesRecruitingStroke, Ischemic | Stroke HemorrhagicItaly
-
Sheffield Teaching Hospitals NHS Foundation TrustUnknownFatigue | Stroke, Ischemic | Stroke HemorrhagicUnited Kingdom
-
BayerRecruitingAcute Non-cardioembolic Ischemic Stroke | Prevention of Ischemic Stroke | High-risk Transient Ischemic AttackUnited States, Switzerland, Belgium, Australia, Sweden, Canada, Taiwan, Spain, Korea, Republic of, Latvia, Israel, Malaysia, China, Greece, Japan, Turkey, Netherlands, Romania, United Kingdom, Portugal, Hungary, Italy, Brazil, France, S... and more
-
University of AlbertaCompletedTransient Ischemic Attack | Minor Ischemic StrokeCanada
-
Stephanie HarrisonActive, not recruitingTransient Ischemic Attack | Stroke, IschemicUnited Kingdom
Clinical Trials on Intra-arterial administration of neuroprotective agents
-
Hui-Sheng ChenActive, not recruitingIschemic Stroke | NeuroprotectionChina
-
Rennes University HospitalTerminatedHepatocellular CarcinomaFrance
-
General Hospital of Shenyang Military RegionCompleted
-
Stanford UniversityWithdrawnRetinoblastoma | Eye CancerUnited States
-
Hui-Sheng ChenRecruiting
-
Maastricht UniversityRecruitingMitochondrial MyopathiesNetherlands
-
Universitaire Ziekenhuizen KU LeuvenWithdrawn
-
Hui-Sheng ChenCompleted
-
Northwell HealthRecruitingGlioblastoma | Brain Cancer | Brain Tumor | GBM | Brain Neoplasm | Brain Neoplasm, Malignant | EGFR Gene OverexpressionUnited States